Back to research

Entity Setup

Entity Structuring Insights: Expanding EMI, EIS, & VCT for Scale-Ups

From 6 April 2026, UK law expands eligibility and limits for EMI, Enterprise Investment Scheme (EIS), and Venture Capital Trusts (VCT), creating powerful tools for start-ups and scale-ups to attract investment and talent.

By NomadicTax Research Team · 5-8 min read

Overview of Schemes & What's Changing

The UK’s EMI, EIS, and VCT schemes are tax-advantaged routes to support businesses and investors. Under recent reforms:

  • EMI (Enterprise Management Incentives) limits will double or more: company option cap from £3 million to £6 million; gross asset threshold from £30 million to £120 million; employee number from 250 to 500; holding/exercise period extended from 10 to 15 years. (gov.uk)
  • EIS and VCT changes include doubling investment limits and gross asset thresholds. Also, VCT upfront income tax relief drops from 30% to 20% to balance incentives. (gov.uk)
  • These changes are effective from 6 April 2026. EMI exercise period extension also applies to existing contracts that haven’t lapsed or been exercised. (gov.uk)

Strategic Benefits for Scale-Ups & Investors

  • Employee attraction & retention: wider eligibility under EMI enables more companies to reward staff with tax‐efficient share options, aligning employee success with company growth.
  • Investor incentives: EIS/VCT limits increased mean more capital can flow into early-stage firms, potentially improving late seed or Series A funding.
  • Tax relief balancing: Though VCT relief reduced, the higher limits may offset impact for some investors.

Practical Steps for Entities & Founders

  1. Review corporate structure: Ensure your company meets the expanded thresholds (gross assets, number of employees) to qualify.
  2. Plan for share option design: If you're issuing options, update exercise periods; consider amending existing EMI contracts to extend them to 15 years if beneficial.
  3. Investor communication: If raising via EIS/VCT, transparently communicate changes in relief and thresholds—they could affect investor decisions.
  4. Tax advice: Engage specialists early to manage legal drafting, share valuation, and filings (e.g. EMI notifications and end-of-year ERS returns).
  5. Monitor timing: Ensure grants or investments fall on or after 6 April 2026 to benefit from new thresholds.

Illustrative Example

Startup “GreenAI Ltd” in biotech has 350 employees and £25m in assets by March 2026. Previously not eligible for EMI (employee cap 250), they couldn’t offer share options to late-hire talent. After reforms, from 6 April 2026, they can issue up to £6m in share option value, include more employees, and allow options to be exercised over 15 years. Also, an investor using VCT can invest more into GreenAI, though relief drops from 30% to 20%, the investment cap increase makes it still attractive.

Risks & Considerations

  • Specified company restrictions: Companies in Northern Ireland trading in goods or electricity are classified as “specified companies” and do not benefit from extended exercise periods even if other thresholds pass. (gov.uk)
  • Administrative burden: Higher limits mean more complex valuation, legal documentation, and reporting (EMI notifications by 6 July, ERS returns, etc.).
  • Tax relief uncertainty for investors: VCT relief falls—affects net return; investors may prefer EIS under certain risk/return profiles.

Action Items for Entities & Investors

  • Audit your growth plans and whether thresholds will be exceeded or met.
  • Update or consult your share-scheme documentation; amend existing EMI contracts where possible.
  • Ensure grant dates and filings align with legislative windows.
  • Educate employees on tax implications of share options (Income Tax, CGT).
  • For investors, model returns under new relief percentages and limits to ensure net benefits.

These reforms make UK entity structure and investment strategy more flexible—smart planning can unlock major upside.

Sources

Structured source metadata was not recorded; see citations in the article body.